Filament Health has received FDA authorization to initiate the first clinical trial using naturally sourced psychedelic substances. The phase 1 trial will include 20 healthy subjects and examine the effects of Filament's three proprietary botanical drug candidates. CEO Benjamin Lightburn sat down with Caroline Egan to discuss the clinical trial.

For the full interview with Benjamin Lightburn and to learn more about Filament Health's clinical trial, click here.